āĻšā§āĻŽNB3 âĸ FRA
add
Neurocrine Biosciences Inc
ā§§ā§Ļā§.ā§ā§ĻâŦ
ā§¨ā§ āĻā§āĻ¨, ā§§ā§Ļ:ā§Ģā§¯:ā§Ēā§Ļ PM GMT +ā§¨ · EUR · FRA · āĻĄāĻŋāĻ¸āĻā§āĻ˛ā§āĻŽāĻžāĻ°
āĻ¸ā§āĻāĻDE-āĻ āĻ¤āĻžāĻ˛āĻŋāĻāĻžāĻā§āĻā§āĻ¤ āĻ¸āĻŋāĻāĻŋāĻāĻ°āĻŋāĻāĻŋāĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ āĻ¯ā§āĻā§āĻ¤āĻ°āĻžāĻˇā§āĻā§āĻ°-āĻ āĻšā§āĻĄāĻā§ā§āĻžāĻ°ā§āĻāĻžāĻ°
āĻāĻžāĻ˛ āĻļā§āĻˇ āĻ¯ā§ āĻĻāĻžāĻŽā§ āĻāĻŋāĻ˛
ā§§ā§Ļā§Ž.ā§Šā§ĻâŦ
āĻ¸āĻžāĻ°āĻž āĻĻāĻŋāĻ¨ā§āĻ° āĻā§āĻ°ā§āĻĄāĻŋāĻā§ā§ āĻ¸ā§āĻāĻā§āĻ° āĻĻāĻžāĻŽā§āĻ° āĻāĻ āĻž āĻ¨āĻžāĻŽāĻžāĻ° āĻ°ā§āĻā§āĻ
ā§§ā§Ļā§.ā§ā§ĻâŦ - ā§§ā§Ļā§.ā§ā§ĻâŦ
āĻ¸āĻžāĻ°āĻž āĻŦāĻāĻ°ā§āĻ° āĻ°ā§āĻā§āĻ
ā§ā§.ā§ā§ŽâŦ - ā§§ā§Ēā§.ā§Ēā§ĢâŦ
āĻŽāĻžāĻ°ā§āĻā§āĻ āĻā§āĻ¯āĻžāĻĒ
ā§§ā§¨.ā§Ēā§§āĻļāĻ¤Â āĻā§ USD
āĻāĻĄāĻŧ āĻāĻ˛āĻŋāĻāĻŽ
ā§§ā§Š.ā§Ļā§Ļ
P/E āĻ
āĻ¨ā§āĻĒāĻžāĻ¤
-
āĻ˛āĻā§āĻ¯āĻžāĻāĻļ āĻĒā§āĻ°āĻĻāĻžāĻ¨
-
āĻĒā§āĻ°āĻžāĻāĻŽāĻžāĻ°āĻŋ āĻāĻā§āĻ¸āĻā§āĻā§āĻ
NASDAQ
āĻāĻŦāĻ°ā§ āĻ°ā§ā§āĻā§
āĻĢāĻžāĻāĻ¨āĻžāĻ¨ā§āĻ¸āĻŋā§āĻžāĻ˛ āĻĒāĻžāĻ°āĻĢāĻ°ā§āĻŽā§āĻ¯āĻžāĻ¨ā§āĻ¸
āĻā§ā§āĻ° āĻ¸ā§āĻā§āĻāĻŽā§āĻ¨ā§āĻ
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ
| (USD) | āĻŽāĻžāĻ°ā§āĻ ā§¨ā§Ļā§¨ā§Ģinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§Ģā§.ā§¨ā§Ŧ āĻā§ | ā§§ā§§.ā§§ā§¨% |
āĻŦā§āĻ¯āĻŦāĻ¸āĻž āĻāĻžāĻ˛āĻžāĻ¨ā§āĻ° āĻāĻ°āĻ | ā§¨ā§.ā§Ŧā§Ģ āĻā§ | ā§§ā§Š.ā§ā§Ē% |
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | ā§ā§¯.ā§Ļā§Ļ āĻ˛āĻž | -ā§Žā§§.ā§Žā§Ļ% |
āĻ¨ā§āĻ āĻĒā§āĻ°āĻĢāĻŋāĻ āĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ | ā§§.ā§Šā§Ž | -ā§Žā§Š.ā§Ŧā§§% |
āĻļā§ā§āĻžāĻ° āĻĒā§āĻ°āĻ¤āĻŋ āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§Ļ.ā§ā§Ļ | -ā§Ēā§§.ā§Ŧā§% |
EBITDA | ā§Š.ā§§ā§ŠÂ āĻā§ | -ā§ā§§.ā§¯ā§Š% |
āĻĒā§āĻ°āĻ¯ā§āĻā§āĻ¯ āĻā§āĻ¯āĻžāĻā§āĻ¸ā§āĻ° āĻšāĻžāĻ° | ā§Ēā§Ŧ.ā§¨ā§Ŧ% | â |
āĻŦā§āĻ¯āĻžāĻ˛ā§āĻ¨ā§āĻ¸ āĻļāĻŋāĻ
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (USD) | āĻŽāĻžāĻ°ā§āĻ ā§¨ā§Ļā§¨ā§Ģinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻā§āĻ¯āĻžāĻļ āĻ āĻāĻŽ āĻ¸āĻŽā§ā§āĻ° āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ | ā§¯ā§Ē.ā§Šā§Ģ āĻā§ | -ā§¨ā§¨.ā§Ļā§Ŧ% |
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ | ā§Šā§Ŧā§Ž.ā§ā§Â āĻā§ | ā§Ŧ.ā§¨ā§Ļ% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§§ā§§ā§Ģ.ā§¨ā§Ļ āĻā§ | ā§Ŧ.ā§Ļā§Ģ% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§¨ā§Ģā§Š.ā§Ģā§Â āĻā§ | â |
āĻāĻāĻāĻ¸ā§āĻā§āĻ¯āĻžāĻ¨ā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāĻ° | ā§¯.ā§¯ā§Ļ āĻā§ | â |
āĻĒā§āĻ°āĻžāĻāĻ¸ āĻā§ āĻŦā§āĻ āĻ°ā§āĻļāĻŋāĻ | ā§Ē.ā§¨ā§Š | â |
āĻ¸āĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | ā§§.ā§Ŧā§Ļ% | â |
āĻŽā§āĻ˛āĻ§āĻ¨ āĻĨā§āĻā§ āĻā§ | ā§§.ā§¯ā§Ē% | â |
āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨
| (USD) | āĻŽāĻžāĻ°ā§āĻ ā§¨ā§Ļā§¨ā§Ģinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | ā§ā§¯.ā§Ļā§Ļ āĻ˛āĻž | -ā§Žā§§.ā§Žā§Ļ% |
āĻ
āĻĒāĻžāĻ°ā§āĻļāĻ¨ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āĻ¯āĻžāĻļ | ā§Ŧ.ā§Ēā§ŽÂ āĻā§ | -ā§Ģā§Ļ.ā§¨ā§% |
āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | ā§§.ā§Ēā§¨Â āĻā§ | ā§§ā§¨ā§Ģ.ā§Žā§¨% |
āĻĢāĻžāĻāĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¸āĻŋāĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | -ā§§ā§§.ā§ā§¯Â āĻā§ | -ā§¨ā§Ŧā§Ž.ā§Ŧā§% |
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ | -ā§Š.ā§Žā§¯Â āĻā§ | -ā§§ā§¨ā§Ŧ.ā§ā§¯% |
āĻĢā§āĻ°āĻŋ āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§ | ā§¨.ā§Žā§¯Â āĻā§ | -ā§Žā§Ž.ā§Ģā§Ļ% |
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻā§
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
āĻ¸āĻŋāĻāĻ
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāĻ¤ āĻšā§ā§āĻā§
ā§§ā§¯ā§¯ā§¨
āĻ¸āĻĻāĻ° āĻĻāĻĒā§āĻ¤āĻ°
āĻā§ā§āĻŦāĻ¸āĻžāĻāĻ
āĻāĻ°ā§āĻŽāĻāĻžāĻ°ā§
ā§§,ā§Žā§Ļā§Ļ
